Citadel Advisors
ELVN icon

Citadel Advisors’s Enliven Therapeutics ELVN Stock Holding History

Citadel Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.65M Sell
72,000
-19,500
-21% -$828K ﹤0.01% 5291
2026
Q1 		$3.59M Buy
91,500
+73,800
+417% +$2.04M ﹤0.01% 4919
2025
Q4 		$273K Buy
+17,700
New +$353K ﹤0.01% 10357
2025
Q2 		– Sell
-900
Closed -$17.7K – 13161
2025
Q1 		$17.7K Buy
900
+600
+200% +$12.9K ﹤0.01% 13229
2024
Q4 		$6.75K Sell
300
-200
-40% -$5.18K ﹤0.01% 13779
2024
Q3 		$12.8K Sell
500
-100
-17% -$2.32K ﹤0.01% 13087
2024
Q2 		$14K Buy
+600
New +$12.6K ﹤0.01% 12907
2023
Q2 		– Sell
-250
Closed -$5.47K – 14530
2023
Q1 		$5.47K Sell
250
-4,450
-95% -$90.5K ﹤0.01% 13869
2022
Q4 		$76.9K Sell
4,700
-11,225
-70% -$179K ﹤0.01% 11569
2022
Q3 		$145K Buy
+15,925
New +$94K ﹤0.01% 10740

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Citadel Advisors's ELVN Position: Q2 2026 in Review

Citadel Advisors increased its Enliven Therapeutics (ELVN) stake by 19% in Q2 2026, buying an estimated $13.8M and bringing the position to 2,068,992 shares worth $105M. The position accounts for 0.01% of the portfolio, ranked #944.

Citadel Advisors first reported a position in ELVN in Q1 2020 and has held it in 17 quarters since. 211 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Citadel Advisors held 2,068,992 shares of Enliven Therapeutics worth $105M as of Q2 2026.
  • Citadel Advisors bought 325,077 Enliven Therapeutics shares in Q2 2026, an estimated $13.8M.
  • Enliven Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q2 2026, its #944 holding.
  • Citadel Advisors first reported a position in Enliven Therapeutics in Q1 2020 and has held it in 17 quarters since.
  • 211 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.